Equinor and Cognite Enter Partnership to Accelerate Digital Ambitions Within Global Marketing and Supply
20.12.2021 16:55:00 EET | Business Wire | Press release
Cognite today announced a collaboration with Equinor (OSE: EQNR, NYSE: EQNR), a world-leading energy company, to expand Equinor’s data capabilities and support the company’s digital ambitions.
Using Cognite’s industrial DataOps technology, Cognite Data Fusion®, as a module in Equinor’s OMNIA data architecture, built on the Microsoft Azure cloud, a joint Equinor and Cognite team will develop and explore tools and solutions to accelerate Equinor’s digital ambitions. These efforts include developing data-driven insights within Marketing & Supply and other business areas across Equinor’s global footprint and asset portfolio.
Equinor’s ambition is to develop an advanced analytical ecosystem with highly accessible data and insights generation through enhanced digital capabilities. Equinor and Cognite, in collaboration with Microsoft, will build solutions to liberate and contextualize data, creating a competitive edge in highly complex and dynamic global markets. The partnership will focus on building a future-proof data architecture, new ways of working, and accelerating data extraction and contextualization.
“Leveraging Cognite and Microsoft technology and competence, working closely with our own teams, will help drive our ambition to take a leading role in the digital step-up happening in global commodity markets,'' says Ann-Elisabeth Serck-Hanssen, SVP Marketing & Supply in Equinor.
“Liberation, integration, and contextualization of data will be a key accelerator and a critical differentiator in the markets of the future, and Equinor’s ambition is to become a leader in the way we manage and derive insights from data,” says Torbjørn Folgerø, SVP Enterprise Digital in Equinor.
With contextualized data, Equinor can develop accessible data models and analytics, empowering employees to develop competitive insights and stress-test hypotheses on a continuous basis.
“We are very proud to establish a partnership with Equinor, a world leading energy company with a global portfolio of market operations,” says Dr. John Markus Lervik CEO and co-founder of Cognite. “Data liberation and DataOps in commercial operations will be a key differentiator for Equinor in the global energy markets, and a critical enabler for next-generation decision support, quality, resilience, and competitiveness. Partnering with Equinor to help support their digital ambitions is not only a great opportunity to demonstrate the power of contextualized data, but also to show the value of close cross-functional teamwork.”
About Equinor
Equinor develops oil, gas and new energy solutions for today and tomorrow, turning natural resources into energy for people and progress for society. Equinor has more than 40 years of experience developing oil and gas on the Norwegian Continental shelf and now operates in more than 30 countries. The company is headquartered in Stavanger, Norway, listed on the New York and Oslo stock exchanges and employs approximately 22,000 people worldwide.
About Cognite
Cognite is a global industrial SaaS company that was established with one clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-heavy industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com, and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005440/en/
Contact information
Press contact - Equinor
Magnus Franzen Eidsvold,
Manager media relations
mfei@equinor.com
Press contact - Cognite
Michelle Holford
Global PR Lead - Cognite
michelle.holford@cognite.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom